A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Topical laquinimod reaches posterior eye tissues with dose-related distribution and good tolerability in patients preparing for vitrectomy
The biotech sector saw compelling developments from funding milestones to shifts in trial regulations and rising promise in …
New AI-powered system promises to reduce inefficiencies in trial recruitment by automating eligibility prediction
Clinical-stage companies AC Immune and Edgewise Therapeutics shared encouraging updates on their immunotherapy and cardiac medicine programs, signaling …
MaaT Pharma advances its microbiome ecosystem therapies with new preclinical evidence showing enhanced patient immunotherapy responses.
Experimental gene-silencing drug lepodisiran delivers long-lasting reduction of cardiovascular risk factor, while Spinogenix launches trial for novel synaptic …
Alnylam’s Fitusiran gains FDA approval as a first RNAi therapeutic for hemophilia, while Vertex discontinues its innovative insulin-producing …
The FDA approval of Alnylam’s Fitusiran marks a milestone in RNA interference therapeutics, while Vertex discontinues a novel …
Already a subscriber? Log in